Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its position in Laboratory Co. of America Holdings (NYSE:LHFree Report) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,728 shares of the medical research company’s stock after selling 281 shares during the period. Janney Montgomery Scott LLC’s holdings in Laboratory Co. of America were worth $6,178,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. First Horizon Advisors Inc. lifted its stake in shares of Laboratory Co. of America by 1.7% in the second quarter. First Horizon Advisors Inc. now owns 2,843 shares of the medical research company’s stock valued at $686,000 after purchasing an additional 47 shares during the period. Neuberger Berman Group LLC lifted its stake in shares of Laboratory Co. of America by 0.6% in the fourth quarter. Neuberger Berman Group LLC now owns 7,834 shares of the medical research company’s stock valued at $1,845,000 after purchasing an additional 48 shares during the period. SP Asset Management LLC lifted its stake in shares of Laboratory Co. of America by 0.3% in the second quarter. SP Asset Management LLC now owns 14,901 shares of the medical research company’s stock valued at $3,596,000 after purchasing an additional 50 shares during the period. Essex Financial Services Inc. lifted its stake in shares of Laboratory Co. of America by 1.9% in the second quarter. Essex Financial Services Inc. now owns 2,669 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 50 shares during the period. Finally, Guardian Wealth Management Inc. lifted its stake in shares of Laboratory Co. of America by 1.0% in the first quarter. Guardian Wealth Management Inc. now owns 5,379 shares of the medical research company’s stock valued at $1,418,000 after purchasing an additional 52 shares during the period. Hedge funds and other institutional investors own 89.37% of the company’s stock.

Laboratory Co. of America Stock Performance

Shares of NYSE LH opened at $222.59 on Monday. The company has a market cap of $18.90 billion, a PE ratio of 29.76 and a beta of 1.04. Laboratory Co. of America Holdings has a 12 month low of $174.20 and a 12 month high of $234.09. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.20. The company has a 50-day simple moving average of $223.49 and a 200-day simple moving average of $213.20.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.72 dividend. The ex-dividend date is Monday, February 26th. This represents a $2.88 dividend on an annualized basis and a yield of 1.29%. Laboratory Co. of America’s payout ratio is 38.50%.

Insider Activity at Laboratory Co. of America

In related news, EVP Der Vaart Sandra D. Van sold 259 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total value of $57,513.54. Following the completion of the sale, the executive vice president now directly owns 7,637 shares in the company, valued at $1,695,872.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Laboratory Co. of America news, CAO Peter J. Wilkinson sold 1,384 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $210.71, for a total transaction of $291,622.64. Following the completion of the sale, the chief accounting officer now directly owns 2,087 shares in the company, valued at $439,751.77. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Der Vaart Sandra D. Van sold 259 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total transaction of $57,513.54. Following the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at $1,695,872.22. The disclosure for this sale can be found here. 0.65% of the stock is owned by insiders.

Analysts Set New Price Targets

LH has been the subject of several recent analyst reports. TheStreet upgraded shares of Laboratory Co. of America from a “c+” rating to a “b-” rating in a research note on Thursday, January 18th. JPMorgan Chase & Co. lifted their target price on shares of Laboratory Co. of America from $259.00 to $261.00 and gave the stock an “overweight” rating in a research report on Friday, November 17th. Mizuho cut their target price on shares of Laboratory Co. of America from $257.00 to $230.00 and set a “buy” rating for the company in a research report on Tuesday, October 31st. Evercore ISI initiated coverage on shares of Laboratory Co. of America in a research report on Friday. They set an “in-line” rating and a $240.00 target price for the company. Finally, Barclays initiated coverage on shares of Laboratory Co. of America in a research report on Wednesday, January 3rd. They set an “equal weight” rating and a $222.00 target price for the company. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Laboratory Co. of America has an average rating of “Moderate Buy” and a consensus target price of $241.86.

View Our Latest Research Report on LH

Laboratory Co. of America Company Profile

(Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.

Featured Stories

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LHFree Report).

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.